WallStreetZenWallStreetZen

NASDAQ: RWLK
Rewalk Robotics Ltd Stock

$0.76+0.02 (+2.7%)
Updated Sep 29, 2023
RWLK Price
$0.76
Fair Value Price
$1.80
Market Cap
$45.55M
52 Week Low
$0.56
52 Week High
$1.01
P/E
-2.38x
P/B
0.77x
P/S
6.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.63M
Earnings
-$19.74M
Gross Margin
36.2%
Operating Margin
-354.6%
Profit Margin
-350.4%
Debt to Equity
0.12
Operating Cash Flow
-$17M
Beta
0.69
Next Earnings
Nov 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A

RWLK Overview

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RWLK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RWLK ($0.76) is undervalued by 57.77% relative to our estimate of its Fair Value price of $1.80 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RWLK ($0.76) is significantly undervalued by 57.77% relative to our estimate of its Fair Value price of $1.80 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RWLK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RWLK due diligence checks available for Premium users.

Be the first to know about important RWLK news, forecast changes, insider trades & much more!

RWLK News

Valuation

RWLK fair value

Fair Value of RWLK stock based on Discounted Cash Flow (DCF)
Price
$0.76
Fair Value
$1.80
Undervalued by
57.77%
RWLK ($0.76) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RWLK ($0.76) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RWLK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RWLK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.38x
Industry
48.82x
Market
12.37x

RWLK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.77x
Industry
3.49x
RWLK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RWLK's financial health

Profit margin

Revenue
$1.3M
Net Income
-$4.6M
Profit Margin
-347.2%
RWLK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RWLK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$65.8M
Liabilities
$6.8M
Debt to equity
0.12
RWLK's short-term assets ($63.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RWLK's short-term assets ($63.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RWLK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RWLK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.5M
Investing
$0.0
Financing
-$215.0k
RWLK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RWLK vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
RWLK$45.55M+3.40%-2.38x0.77x
SRTS$45.41M+4.53%19.79x0.99x
RPID$45.72M-0.92%-0.77x0.33x
EAR$45.05M-0.41%-0.22x0.75x
IRIX$41.22M+22.71%-5.29x3.06x

Rewalk Robotics Stock FAQ

What is Rewalk Robotics's quote symbol?

(NASDAQ: RWLK) Rewalk Robotics trades on the NASDAQ under the ticker symbol RWLK. Rewalk Robotics stock quotes can also be displayed as NASDAQ: RWLK.

If you're new to stock investing, here's how to buy Rewalk Robotics stock.

What is the 52 week high and low for Rewalk Robotics (NASDAQ: RWLK)?

(NASDAQ: RWLK) Rewalk Robotics's 52-week high was $1.01, and its 52-week low was $0.56. It is currently -24.75% from its 52-week high and 35.71% from its 52-week low.

How much is Rewalk Robotics stock worth today?

(NASDAQ: RWLK) Rewalk Robotics currently has 59,937,017 outstanding shares. With Rewalk Robotics stock trading at $0.76 per share, the total value of Rewalk Robotics stock (market capitalization) is $45.55M.

Rewalk Robotics stock was originally listed at a price of $640.00 in Sep 12, 2014. If you had invested in Rewalk Robotics stock at $640.00, your return over the last 9 years would have been -99.88%, for an annualized return of -52.69% (not including any dividends or dividend reinvestments).

How much is Rewalk Robotics's stock price per share?

(NASDAQ: RWLK) Rewalk Robotics stock price per share is $0.76 today (as of Sep 29, 2023).

What is Rewalk Robotics's Market Cap?

(NASDAQ: RWLK) Rewalk Robotics's market cap is $45.55M, as of Oct 1, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Rewalk Robotics's market cap is calculated by multiplying RWLK's current stock price of $0.76 by RWLK's total outstanding shares of 59,937,017.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.